Multi-Endpoint Studies

Combination studies integrate the analysis of multiple endpoints to evaluate the genotoxic risk of a compound.  Utilizing a 3-dose protocol design, the in vivo rat bone marrow micronucleus assay, in vivo Comet assay, and flow cytometric peripheral blood micronucleus assay are combined into one protocol.  Based on individual assay result data and published literature, the results of multi-endpoint assays are highly predictable for evaluating genotoxic risk.

Key advantages to using multi-endpoint assays include:

  • Up to 70% reduction in animals needed for rodent studies
  • Obtain more toxicity information in a quicker timeframe
  • Less test article required due to need for fewer animals
  • Evaluate toxicity in a wide range of tissues
Voice of the Scientist
View a presentation of a Covance scientist discussing Multi-Endpoint Assay.

Download a scientific poster on the following topic:

Home | Animal Welfare | Privacy Statement | Terms of Use | Cookie Statement | Contact Us | Site Map | Investigators | Covance.Asia
RSS © Copyright 2014 Covance Inc. All rights reserved.